Brahim_av schreef op 26 augustus 2022 12:01:
Mayne reports FY22 results.
www.maynepharma.com/wp-content/upload...NEXTSTELLIS® oral contraceptive: US highlights
> ~70,000 cycles in FY22 with 35,000 cycles in 4QFY22 up 69% from 3QFY221
> 4,760 NEXTSTELLIS new writers since launch; averaging 100 new writers / week and ~1,000
return writers on a weekly basis
> Productivity / writer is increasing with top decile writers averaging 19 cycles / quarter
> Commercial coverage2: 70% formulary access, 55% unrestricted
> Medicaid: 99.5% formulary access, 35% unrestricted
> ~60% of top decile prescribers writing NEXTSTELLIS®
> Consumer campaign launched
> NEXTSTELLIS® nominated for 2022 Prix Galien USA Award for Best Pharmaceutical Agent
NEXTSTELLIS®
> NEXTSTELLIS® revenues were US$4.2m, up 50% on FY21
- 2HFY22 revenues were US$3.2m, up 200% on 1HFY22
- Inventory stocking in June 2021 now normalised
> NEXTSTELLIS® direct operating expenses were US$35m